)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
4DMedical
4DMedical (4DX) investor relations material
4DMedical Q1 2027 TU earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q1 2027 TU earnings summary27 Oct, 2026
Executive summary
Record Q1 FY27 activity: 119,672 scans, up 61% YoY, and 724 global sites, up 77% YoY; CT:VQ adoption expanded across the U.S., Europe and Australia.
Unaudited operating revenue was $2.3m, up 66% YoY, with gross margins above 90%; quarter-end cash was $242.8m.
Financial highlights
Q1 FY27 operating revenue of $2.3m, up 66% YoY, driven by CT:VQ adoption and increased scan volumes; gross margins remained above 90%.
Customer receipts were $1.612m; net operating cash outflow was $15.174m, including $0.8m of one-off contextflow acquisition costs.
Cash and cash equivalents declined from $277.954m to $242.763m during the quarter.
Outlook and guidance
The major U.S. Veterans Affairs network agreement is expected to generate approximately US$800,000 over five years, with an initial one-year term and annual extensions.
CLEAR recruitment and site activation tracked to plan, supporting a targeted CY2027 readout on CT:VQ in acute pulmonary embolism.
Curagita-led German screening deployment covers approximately 25,000 procedures across 25 sites over three years.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from 4DMedical
- CT:VQ growth plans advance amid shareholder pushback on executive pay.4DX
AGM 2026 - Functional lung imaging gains rapid adoption, improving outcomes and expanding globally.4DXLife Sciences Virtual Investor Forum Conference
- Strong FY26 growth with FDA-cleared CT:VQ™, 21% revenue rise, and $278M cash for expansion.4DXH2 2026
- CT-based lung imaging technology is rapidly replacing nuclear scans, driving strong growth and margins.4DXLife Sciences Virtual Investor Forum
- CT:VQ™ adoption accelerates globally, driving SaaS growth and robust financial performance.4DXQ3 2026 TU
- CLEAR study, SimonMed deal, and European acquisition drive global lung health expansion.4DXInvestor update
- CT:VQ drives improved lung therapy outcomes, workflow efficiency, and rapid clinical adoption.4DXStatus update
- CT-based imaging is set to replace nuclear VQ scans, driving rapid growth and market expansion.4DXAI & Technology Virtual Investor Conference
- FDA clearance, Philips deal, and SaaS growth drive revenue up 56%, but losses persist.4DXH2 2025
Next 4DMedical earnings date
H1 202725 Feb, 2027
4DMedical
Next 4DMedical earnings date
H1 202725 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
4DMedical Limited is an Australia-based medical technology company specializing in advanced imaging solutions for respiratory diagnostics. The company has developed proprietary software that generates four-dimensional lung imaging from X-ray scans, providing detailed, real-time insights into lung function. 4DMedical’s technology is designed to assist healthcare providers in diagnosing and monitoring respiratory conditions such as asthma, chronic obstructive pulmonary disease (COPD), and COVID-19-related lung issues. The company is headquartered in Melbourne, Australia, and its shares are listed on the ASX.